At a Glance
Tesamorelin and CJC-1295 are both GHRH analogs — synthetic peptides modeled on growth-hormone-releasing hormone — studied in growth-hormone secretagogue research. They are frequently compared because they take two different design routes to the same receptor target: tesamorelin stabilizes the full GHRH peptide, while CJC-1295 modifies the shorter GRF(1-29) active fragment.
| Attribute | Tesamorelin | CJC-1295 |
|---|---|---|
| Compound class | GHRH analog peptide | GHRH analog peptide |
| Based on | Stabilized full-length GHRH | Modified GRF(1-29) fragment |
| Peptide length | Longer (full GHRH-based) | Shorter (29-residue-based) |
| CAS number | 218949-48-5 | 863288-34-0 |
| Common variants | Single form | With DAC & No DAC (Mod GRF 1-29) |
| Half-life design | Stabilized analog | DAC variant engineered for extended half-life |
| Research focus | GH-release signaling models | GH-release signaling models |
| Physical form | Lyophilized powder | Lyophilized powder |
| Intended use | Laboratory research only | Laboratory research only |
Mechanism Context
Both compounds are studied as agonists at the GHRH receptor — the receptor that, when activated, participates in growth-hormone-release signaling. As GHRH analogs they sit in the broader "growth-hormone secretagogue" research category.
Tesamorelin is a stabilized synthetic analog of the complete GHRH peptide, engineered with modifications that improve stability relative to native GHRH.
CJC-1295 is built on GRF(1-29) — the first 29 residues of GHRH, which retain receptor activity. Its defining research feature is the optional DAC (drug affinity complex): the with-DAC variant binds albumin to extend half-life in research models, while the no-DAC variant (Mod GRF 1-29) is shorter-acting. This makes CJC-1295 a useful tool for studying how half-life engineering changes a GHRH analog's profile.
The DAC Distinction
When researchers compare these two, the CJC-1295 DAC variable is often the focus. Tesamorelin offers one stabilized design; CJC-1295 offers a two-variant system (with and without DAC) that lets a study directly examine the effect of albumin-binding half-life extension. Selection depends on whether a research design needs that comparison.
Which Should a Study Use?
Neither is "better" — they are different research tools within the same GHRH-analog family. A study examining a stabilized full-length GHRH analog would reach for tesamorelin; a study examining the GRF(1-29) fragment or half-life engineering would reach for CJC-1295. Both fall under the growth-hormone secretagogue research area in the Research Hub.
Tesamorelin and CJC-1295 are sold strictly for laboratory and in-vitro research. They are not for human consumption, veterinary use, or any diagnostic or therapeutic application. This comparison is research reference material, not medical or dosing advice.